Escope esFFR, the fully automated coronary CT-FFR analysis platform created by Escope Technology, recently got approval from China NMPA and will soon be commercially available. Escope Technology developed the first fully automated CT-FFR analysis system worldwide as a result of their relentless efforts to improve product performance. With the development of its professional imaging data analysis platform related to cardiovascular and cerebrovascular disease, Escope Technology will embark on a new adventure.
The NMPA’s approval of ESCOPE esFFR technology is a significant turning point in the company’s pursuit of product research and development. Soon, a series of cardiovascular and cerebrovascular imaging products will be available for structural and functional analysis. We will keep creating cutting-edge computational medicine products, offering more comprehensive and systematic information technology supports for the diagnosis and treatment of cardiovascular and cerebrovascular diseases, and ultimately supporting Health China 2030 by advancing the field of precision medicine and safeguarding people’s lives and health.
Interface of ESCOPE esFFR
The approved ESCOPE esFFR is a coronary vessel analysis system that performs fully automated image reconstruction and flow reserve fraction calculation based on CCTA. In less than 5 minutes, ESCOPE esFFR can automatically finish the 3D reconstruction of coronary arteries and deliver patient-specific FFR values for the entire coronary tree. Since the fully automated analysis system is free of human intervention and simple to use, data bias brought on by manual operations is considerably reduced. In the meantime, ESCOPE esFFR avoids the privacy risks associated with medical data breaches. Although automation and accuracy are mutually exclusive concepts most of the time, accuracy is not sacrificed in the pursuit of automation. With the invasive FFR as the gold standard, the overall accuracy is as high as 93.3%.
About Escope
Escope Tech Co., Ltd. is a technology-driven company focusing on the diagnostic techniques for panvascular diseases including heart diseases and brain diseases. In 2017, the company was founded by the talents in the realm of clinical medicine, computer science and mechanical engineering. In the new era of medical diagnosis, data-driven technologies like deep learning and machine learning along with knowledge-driven technologies, such as computational medicine, computational aided engineering, digital twins, etc emerged as the cornerstones of computational medicine. Escope Tech is committed to creating a world-leading medical imaging and data analysis platform for cardiovascular and cerebrovascular diseases. With the help of artificial intelligence, imaging, machine vision, simulation science, data mining and other underlying technologies, the company has achieved fully upgrade of clinics from imaging morphological indicators to imaging functional indicators. At present, our product lines cover the clinical assessments of the following five main fields, which are coronary artery, cardiac/heart function, intracranial artery, cerebral/brain function and peripheral artery.
